Clinical trial
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
NCT00490009 · Susan Knox, Other · Completed
Key facts
| NCT number | NCT00490009 |
|---|---|
| Title | Phase 2 Study of Bexxar in Relapsed/Refractory DLCL |
| Official title | Phase 2 Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL) |
| Lead sponsor | Susan Knox, Other |
| Collaborators | Corixa Corporation Industry GlaxoSmithKline |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Bexxar, Acetaminophen, Diphenhydramine, Potassium Iodide (KI) |
| Enrollment | 9 |
| Start date | Sep 1, 2004 |
| Primary completion | Apr 1, 2010 |
| Completion | Jun 1, 2013 |
| First posted | Jun 22, 2007 |
| Last update posted | Mar 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: